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Abstract: Ototoxicity and nephrotoxicity are potentially irreversible side effects of chemoradiotherapy
with cisplatin in locally advanced head and neck cancer (LAHNC) patients. Several predictive
genetic variants have been described, but as yet none in LAHNC patients. The aim of this study is to
investigate genetic variants as predictors for ototoxicity and nephrotoxicity in LAHNC patients treated
with cisplatin-containing chemoradiotherapy. Our prospective cohort of 92 patients was genotyped
for 10 genetic variants and evaluated for their association with cisplatin-induced ototoxicity (ACYP2,
COMT, TPMT and WFS1) and nephrotoxicity (OCT2, MATE and XPD). Ototoxicity was determined by
patient-reported complaints as well as tone audiometrical assessments. Nephrotoxicity was defined
as a decrease of ≥25% in creatinine clearance during treatment compared to baseline. A significant
association was observed between carriership of the A allele for rs1872328 in the ACYP2 gene and
cisplatin-induced clinically determined ototoxicity (p = 0.019), and not for ototoxicity measured by
tone audiometrical assessments (p = 0.449). Carriership of a T allele for rs316019 in the OCT2 gene was
significantly associated with nephrotoxicity at any time during chemoradiotherapy (p = 0.022), but not
with nephrotoxicity at the end of the chemoradiotherapy. In conclusion, we showed prospectively that
in LAHNC patients genetic variants in ACYP2 are significantly associated with clinically determined
ototoxicity. Validation studies are necessary to prove the added value for individualized treatments
plans in these patients.
Keywords: chemoradiotherapy; cisplatin; ototoxicity; nephrotoxicity; ACYP2; genetic variants; SNP
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1. Introduction
Head and neck cancer is a common type of cancer worldwide [1,2]. The most frequently
used treatment for patients with locally advanced head and neck cancer (LAHNC) is concomitant
chemoradiotherapy with cisplatin, which improves loco-regional control as well as overall survival
compared to radiotherapy alone [3,4]. Chemoradiotherapy can also be applied as adjuvant treatment
in case of a high recurrence risk after surgery. Concomitant chemoradiotherapy with cisplatin however,
induces a high rate of acute toxicities such as mucositis, dysphagia and dermatitis, most of which will
recover with time, but can also induce irreversible ototoxicity and nephrotoxicity [3,5–7].
Ototoxicity, characterized by sensorineural hearing loss, can be an adverse effect of either
systemically administered cisplatin or radiotherapy to the inner ear. Both chemotherapy and
radiotherapy cause lesions in the cochlea, which may lead to ototoxicity [8]. Ototoxicity caused
by cisplatin begins with high frequency loss and is often bilateral, permanent and can be progressive
also after the end of administration of cisplatin [8,9]. Chemotherapy with cisplatin is most often
applied either at a dose of 100 mg/m2 every three weeks for three cycles (high dose) or at a dose of
40 mg/m2 every week for six or seven cycles (intermediate dose) [5,6]. The incidence of ototoxicity in
patients treated with high dose cisplatin is 79% [10]. Besides ototoxicity, another common side effect
of cisplatin is nephrotoxicity that also can be irreversible. However, unlike ototoxicity, part of the
nephrotoxicity can be reduced by hyperhydration with high natriumchloride. The occurrence and
the severity of nephrotoxicity is also related to the cisplatin dose; 100% of the patients treated with
high dose cisplatin experienced nephrotoxicity of any grade compared with 75% of the patients with
intermediate dose cisplatin [7].
With the aim to prevent ototoxicity and nephrotoxicity, several studies have been performed
to identify risk factors and predictive markers. Known clinical risk factors for ototoxicity after
chemoradiation in LAHNC patients are the cumulative dose of cisplatin and cumulative radiation
dose to the cochlea, younger age, good pretreatment hearing, administration of furosemide and
low levels of serum albumin and hemoglobin [11,12]. However, cisplatin-induced toxicity can
only partly be predicted by these factors. Recently, various studies found genetic variants, i.e.,
single nucleotide polymorphisms (SNPs), that are associated with cisplatin-induced side-effects.
Genetic variants in acylphosphatase 2 (ACYP2) and Wolframin ER transmembrane glycoprotein (WFS1)
were identified as predictive markers for hearing loss [13–17]. The ACYP2 gene is expressed in the
cochlea [14]. Mutations in WFS1 can cause progressive deafness after administration of cisplatin [18].
Cisplatin-induced ototoxicity could be related to increased levels of S-adenosylmethionine through
reduced thiopurine S-methyltransferase (TPMT) or catechol O-methyltransferase (COMT) activity.
However, their predictive value for ototoxicity is controversial [19,20]. With respect to nephrotoxicity,
genetic variants in organic cation transporter 2 (OCT2), (multidrug and toxin extrusion 1 (MATE1) and
xeroderma pigmentosum group D (XPD), are believed to be of predictive value [21–24]. OCT2 and
MATE1 are expressed in the human kidney at the basolateral membrane of renal proximal tubules,
and are involved in the secretion of various cationic substances from the circulation into tubular cells.
In that way OCT2 and MATE1 are involved in the cellular uptake of cisplatin [21,23]. XPD is part of the
nucleotide excision repair pathway and is involved in removal of cisplatin and radiotherapy induced
DNA damage [24,25].
However, most of the abovementioned studies showed correlations in a limited number of patients
and thus confirmation of the association between the SNPs and cisplatin related side effect is needed.
Furthermore, the studies were performed in patients with other cancers than LAHNC. Therefore,
the aim of this study is to investigate the relationship between the different SNPs and cisplatin-induced
ototoxicity and nephrotoxicity in LAHNC patients.
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2. Materials and Methods
2.1. Patients and Treatment
A cohort of Dutch patients with pathologically proven LAHNC and treated with cisplatin-based
chemoradiotherapy was prospectively recruited at the Radboud University Medical Center and the
Erasmus University Medical Center in The Netherlands. Eligibility criteria included a minimum age of
18 years and a WHO performance score of 0 or 1. Patients with renal dysfunction defined as a creatinine
clearance below 60 mL/min were not considered eligible. Before inclusion, written informed consent
was obtained from all patients. The local ethical committee waived the study from ethical approval.
Patients were treated with cisplatin-based chemoradiotherapy for either primary treatment or
adjuvant treatment. Concomitant chemoradiotherapy was administered in three different treatment
schedules; (1) Conventional radiotherapy in combination with cisplatin 100 mg/m2 on days 1, 22 and
43; (2) Accelerated radiotherapy combined with cisplatin 40 mg/m2 on a weekly basis for 6 weeks;
(3) Conventional radiotherapy combined with cisplatin 40 mg/m2 on a weekly basis for 7 weeks.
Intensity-modulated radiation therapy (IMRT) was mandatory. Dose to gross tumor volume was 68–70
Gray (Gy) and dose to elective nodal areas 46–50.3 Gy.
Cisplatin was given by infusion in combination with standard prehydration, posthydration
and anti-emetics. If during the treatment the creatinine clearance was below 60 mL/min because
of dehydration, cisplatin was only administered if the creatinine clearance recovered to 60 mL/min
after rehydration. Dose modifications and discontinuation of cisplatin were performed according to
standard local practice.
2.2. Measurements
Tone audiometry was performed according to standard procedures under standardized conditions.
Air-conduction and thresholds were determined at 1, 2, 4, 8, 10, 12.5 and 16 kHz. Bone-conduction
thresholds were measured, from 1 kHz to 8 kHz. According to the study protocol, audiometry was
carried out at baseline, during chemoradiotherapy after 100 mg/m2 or 120 mg/m2 cisplatin as total
dosage at that moment and within 2 months after completion of treatment.
Ototoxicity was scored utilizing two different approaches. In the first approach, clinically
determined ototoxicity, physicians asked their patients to the hearing loss according to the Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03. In the second approach, hearing loss
was classified using the tone audiometric data from baseline and end of treatment based on the ear
with the worst hearing loss. Hearing loss was defined by threshold shifts at 2, 4 or 8 kHz of ≤25 dB
(grade 1), threshold shift of 26–40 dB (grade 2) or threshold shift of ≥40 dB (grade 3). [15]
Additionally, weekly laboratory tests were performed including the creatinine clearance by use of
calculation of the Modification of Diet in Renal Disease (MDRD). Nephrotoxicity was defined as a
decrease of 25% or more in creatinine clearance by the MDRD at any point during treatment compared
to baseline, based on the international accepted Risk, Injury, Failure, Loss and End Stage Renal Disease
(RIFLE) criteria [7]. Blood or saliva (Oragene saliva collection kit, DNA Genotek, Kanata, ON, Canada)
were used for DNA extraction.
2.3. Genotyping
Genotyping of genetic variant in TPMT (rs12201199, rs1800460, rs1142345) and COMT
(rs9332377) were performed using Taqman SNP genotyping according to the instructions of the
manufacturer (ThermoFisher, Nieuwerkerk aan den IJssel, The Netherlands). The other genetic
variants (COMT rs4646316, ACYP2 rs1872328, OCT2/SLC22A2 rs316019, WFS1 rs62283056, XPD/ERCC2
rs13181 and MATE1 rs2289669) were genotyped using Kompetitive Allele Specific PCR (KASPTM,
KASPar-On_Demand assays (Laboratory of the Government Chemist (LGC) Genomics, Hoddesdon,
UK)) according to the instructions of the manufacturer [13,26]. Analysis of the Taqman and KASP
assay was carried out on a 7500FAST Real-Time PCR System (Thermo Fisher, Nieuwerkerk aan den
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IJssel, The Netherlands). Genotypes were scored using 7500 software (v2.0.6, Thermo Fisher). Negative
controls as well duplicates (8%) were included as quality controls for genotyping.
2.4. Statistics
A sample size calculation showed that inclusion of 100 patients in our study would give 80%
power to identify a statistically significant association between a SNP and ototoxicity, assuming a
40% ototoxicity rate, an alpha of 0.05, an allelic odds ratio (OR) of 3, and a minor allele frequency of
10% [19,20].
The association between the SNPs and clinically relevant hearing loss (“yes” vs. “no”) and
between the SNPs and nephrotoxicity (“yes” vs. “no”) were analyzed with a Pearson’s chi-square or
Fisher-exact tests. p-values were tested two-sided and were considered as statistically significant when
<0.05. SPSS version 22 (New York, United States) was used for performing the analyses. Meta-analysis
of the data of ototoxicity and ACYP2 was performed using a fixed-effects model in review Manager
version 5.3 (The Cochrane Collaboration, Oxford, UK).
3. Results
Between August 2013 and February 2017, 103 patients were included in this study. One patient
withdrew consent. In 10 cases no blood or saliva samples were available for DNA analysis. Thus, in total
92 patients were included in the final analysis. Fifty-seven patients were treated with intermediate
dose cisplatin 40 mg/m2 weekly for 6 or 7 weeks, and 35 patients were treated with high dose cisplatin
100 mg/m2 on days 1, 22 and 43. Baseline characteristics are shown in Table 1.
Table 1. Patient characteristics of the 92 patients analyzed. WHO: World Health Organisation
Patient Characteristic Number of Patients (%)
Age mean (range) 57.8 (28–69)
Gender
Male 67 (72.8)
Female 25 (27.2)
WHO score
0 63 (68.5)
1 28 (30.4)
2 1 (1.1)
Treatment indication
Primary treatment 62 (67.4)
Postoperative treatment 29 (31.5)
Primary treatment tumor, postoperative 1 (1.1)
Treatment for lymph nodes
Primary site
Oral cavity 21 (22.8)
Oropharynx 42 (45.7)
Hypopharynx 10 (10.9)
Larynx 13 (14.1)
Unknown primary 4 (4.3)
Nasal vestibule 2 (2.2)
Cisplatin dose
40 mg/m2 57 (61.3)
100 mg/m2 35 (37.6)
Cumulative cisplatin dose (median, range) 240 mg (80–300)
3.1. Ototoxicity
In all 92 patients, data on clinically-determined ototoxicity were available, whereas hearing loss
after treatment based on tone audiometric measurements was available for 79 patients. Of the 92
patients, six patients reported new grade 2 hearing loss and one patient reported grade 3 hearing loss
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at end of treatment. (Table 2) Of these seven patients, four were treated with cisplatin 40 mg/m2 and
three were treated with cisplatin 100 mg/m2. Based on audiometric measurements, of the 79 patients
included in the analysis, 52 patients (65.8%) had grade 1 hearing loss, whereas 16 patients (20.3%)
and 11 patients (13.9%) had grade 2 and 3 hearing loss, respectively (Table 2). Nine of the 11 patients
with grade 3 hearing loss were treated with cisplatin 100 mg/m2. There was no statistically difference
in cumulative cisplatin dose in patients with or without hearing loss when measured clinically or
audiometrically (p = 0.231 and p = 0.142).
Table 2. Ototoxicity and nephrotoxicity. MDRD: Modification of Diet in Renal Disease
Toxicity Number of Patients (%)
Ototoxicity clinically at the end of treatment (n = 92)
None (grade 0 or grade 1) 85 (92.4)
Hearing loss without hearing aid indicated (grade 2) 6 (6.5)
Hearing loss with hearing aid indicated (grade 3) 1 (1.1)
Ototoxicity by tone audiometry (n = 79)
Grade 1 (≤25 dB loss) 52 (65.8)
Grade 2 (26–40 dB loss) 16 (20.3)
Grade 3 (≥40 dB loss) 11 (13.9)
Ototoxicity by audiometry, only bone conduction (n = 55)
Grade 1 (≤25 dB loss) 41 (74.5)
Grade 2 (26–40 dB loss) 11 (20)
Grade 3 (≥40 dB loss) 3 (5.5)
Nephrotoxicity any time during study (n = 92)
MDRD < 25% decrease 39 (42.4)
MDRD ≥ 25% decrease 53 (57.6)
Nephrotoxicity at the end of study (n = 86)
MDRD < 25% decrease 78 (84.8)
MDRD ≥ 25% decrease 8 (8.7)
Unfortunately, bone conduction was only available in 55 patients. Of these 41 patients (74%)
showed no hearing loss, 11 patients (20%) showed mild hearing loss, three patients (6%) suffered
moderate-profound hearing loss. (Table 2)
3.2. Nephrotoxicity
Of the 92 patients, 53 patients (58%) had nephrotoxicity at any time during treatment. (Table 2)
Cumulative cisplatin dose was not different between those patients intentionally treated with high
dose or intermediate dose cisplatin (p = 0.107). In 86 patients end of treatment creatinine clearance
was available. Of these patients, eight (9%) had nephrotoxicity relative to baseline. All eight of these
patients (100%) were treated with cisplatin 100 mg/m2.
3.3. SNP and Ototoxicity
Nine patients were heterozygous GA for the ACYP2 variant rs1872328; all other patients (n = 83)
were homozygous GG. Forty-three percent of the patients reporting clinically hearing loss grade 2
or 3 (3 out of 7 patients) were carrying an A allele, whereas 7% of the patients without clinically
hearing loss (grade 0 or 1) were carrier of the A allele. Association analysis showed a statistically
significant difference between the groups (p = 0.019, OR 9.9, 95% confidence interval (CI) (1.8–54.7)).
We found no differences between carriership of the A allele and ototoxicity based on tone audiometrical
measurements (Table 3). A meta-analysis of the cohorts of the previous published studies performed in
humans also indicated a significant association of the ACYP2 variant with ototoxicity. For this analysis
we used the data of the audiometrical assessments in our patients to compare with the other studies
(Figure 1).
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Table 3. Significance levels for genetic variants related to ototoxicity. * = significantly different (p <
0.05).
Genotype
Clinical No
Ototoxicity N
(%)
Clinical
Ototoxicity N
(%)
p-Value
Audiometrical
Ototoxicity
Grade 1 N (%)
Audiometrical
Ototoxicity
Grade 2 N (%)
Audiometrical
Ototoxicity
Grade 3 N (%)
p-Value
TPMT:rs12201199
AA 77 (91.6) 7 (8.3) p = 1.0 47 (66) 14 (20) 10 (14) p = 0.863
AT/TT 8 (100) 0 (0) 5 (63) 2 (25) 1 (12)
TPMT:rs1142345
TT 77 (91.6) 7 (8.3) p = 1.0 47 (66) 14 (20) 10 (14) p = 0.863
TC/CC 8 (100) 0 (0) 5 (63) 2 (25) 1 (12)
TPMT:rs1800460
CC 77 (91.6) 7 (8.3) p = 1.0 47 (66) 14 (20) 10 (14) p = 0.863
CT/TT 8 (100) 0 (0) 5 (63) 2 (25) 1 (12)
COMT:rs4646316
CC 50 (94) 3 (6) p = 0.452 31 (66) 11 (23) 5 (11) p = 0.459
CT/TT 35 (90) 4 (10) 21 (66) 5 (15) 6 (19)
COMT:rs9332377
CC 66 (93) 5 (7) p = 0.657 40 (66) 11 (18) 10 (16) p = 0.410
CT/TT 19 (90) 2 (10) 12 (67) 5 (28) 1 (5)
ACYP2:rs1872328
GG 79 (95) 4 (5) p = 0.019 * 48 (67) 15 (21) 9 (12) p = 0.499
GA 6 (67) 3 (33) 4 (57) 1 (14) 2 (29)
WFS1:rs62283056
GG 54 (89) 7 (11) p = 0.091 35 (66) 12 (23) 6 (11) p = 0.600
GC/CC 31 (100) 0 (0) p = 0.091 17 (66) 4 (15) 5 (19)
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Figure 1. Forest plot of eta-analysis of ACYP2 rs1872328. eta-analysis of published cohorts in
hu ans and present study using a fixed-effects odel. 95% CI, 95% confidence interval of odds ratio;
-H, antel-Haenszel method.
For the tested genetic variants in TPMT, COMT and WFS1 no statistically differences were found
in either clinically or tone audiometrically assessed hearing loss. (Table 3) Also, the association
analysis in patients with hearing loss using bone conduction as outcome, showed no statistically
significant difference.
3.4. SNP and Nephrotoxicity
Data on the OCT2 gene were available in 93 patients. Eighteen patients were heterozygous GT
for the OCT2 variant rs316019; three patients were homozygous TT and all other 72 patients were
homozygous GG. Thirty percent of the patients with nephrotoxicity during treatment were carrying a T
allele, whereas 12.5% of the patients without nephrotoxicity, which was significantly different (p = 0.049,
OR 3.78 95%CI (1.1–12.4)). No association was found between carriers of the T allele and nephrotoxicity
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at end of treatment compared to baseline (p = 0.845). Nephrotoxicity was not significantly associated
with the analyzed genetic variants in MATE1 and XDP (Table 4).
Table 4. Significance levels for genetic variants related to nephrotoxicity. * = significantly different
(p < 0.05).
Genotype
No nephrotoxicity
During Treatment N
(%)
Nephrotoxicity
during Treatment
N (%)
p-Value
No
Nephrotoxicity at
End of Treatment
N (%)
Nephrotoxicity at
End of Treatment
N (%)
p-Value
OCT2/SLC22A2:rs316019
GG 35 (48.6) 37 (51.4) p = 0.049* 61 (91.0) 6 (9.0) p = 1.00
GT/TT 5 (24.0) 16 (76.0) 18 (89.5) 2 (10.5)
MATE1:rs2289669
GG 15 (42.9) 20 (57.1) p = 1.00 29 (90.6) 3 (9.4) p = 1.00
GA/AA 25 (43.1) 33 (56.9) 50 (90.9) 5 (9.1)
XPD/ERCC2:rs13181
TT 20 (55.6) 16 (44.4) p = 0.085 32 (96.9) 1 (3.1) p = 0.146
TG/GG 20 (35.7) 36 (64.3) 46 (86.8) 7 (13.2)
4. Discussion
Since a high percentage of LAHNC patients treated with cisplatin-based chemoradiotherapy
develop irreversible ototoxicity and nephrotoxicity, it would be worthwhile to add predictive biomarkers
for toxicity to treatment decision-making to avoid these. In this study we investigated whether germline
genetic variants were associated with ototoxicity and nephrotoxicity. We focused on 10 SNPs in seven
genes which were previously reported to be related to these adverse effects [15,16,19,21]. We could
confirm the association between a genetic variant in ACYP2 and clinical reported hearing loss,
but not with tone audiometrical measurements. Moreover, we found an association with OCT2
and nephrotoxicity during treatment with cisplatin, but not with nephrotoxicity at end of treatment,
which makes it not useful in clinical practice.
With our findings we are the fifth group to report on the association between genetic variation in
the ACYP2 gene and cisplatin-induced ototoxicity [13–16]. The initial studies of Xu and Vos reported
that the A allele of the genetic variants rs1872328 in the ACYP2 gene was only present in patients with
ototoxicity, i.e., 13.8% and 6.5%, respectively, carried the A allele. More recent studies, also identified
the A allele in patients without hearing loss, but only in a low percentage (1%) [15]. In contrast to these
studies we found that 57% of the patients without audiometrical measured ototoxicity carried the A
allele and 43% of the patients with mild to moderate audiometrical measured ototoxicity. A study by
Fang et al. described an increased risk of esophageal carcinoma associated with the genetic variant
rs11125529 in the ACYP2 [27]. Although another variant of the A allele was found and a Chinese
population was studied, a genetic variant of the A allele could be related to head and neck cancer and
therefore found more often in our cohort.
We could not find an association between the other variants investigated and ototoxicity. This is
in line with previous studies that showed equivocal results [15,19,20] (Table 5). A possible confounder
in ototoxicity rate in our patient population is radiation in the head and neck region, because radiation
can induce conductive hearing loss as a result of inflammation and edema as well as sensorineural
hearing loss caused by radiation on the inner ear [11]. Although some patients in the studies by Xu et al.
and Ross et al. received cranial radiation as well [14,19].
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Table 5. Overview of performed studies to ototoxicity and cisplatin.
Study Discovery Xu [14] Replication Xu [14] Vos [13] Thiesen [16] Drogemoller [15] Our Study
Patients Children withbrain tumours
Children with brain
tumours
Children (3–43
yrs) with
osteosarcoma
Children with
different
tumours
Testicular cancer Head and neckcancer
Number of patients 238 68 156 149 229 92
Cummulative dose
cisplatin (median, range)
287 mg/m2
(unknown)
Unknown * 480 mg/m
2
(140–720)
378 mg/m2
(60–800)
400 mg/m2
(200–920)
240 mg/m2
(80–300)
Concomitant drugs
Vincristine,
amisfostine,
cyclofosfamide
Vinblastin,
carboplatin
Vincristine,
carboplatin in
some pts
Vincristine,
carboplatin
Etoposide,
bleomycine -
Radiation Craniospinal Focal in some pts 0 Some pts 0 IMRT
* But same cisplatin dose as discovery cohort. IMRT: Intensity-modulated radiation therapy.
There is a great variance in the applied scoring systems for ototoxicity between the studies, as the
initial studies were done in children, most systems are only validated in children [28]. We decided
to perform two analyses, one based on clinical hearing loss and the other on objective audiometrical
assessments. For the audiometrical assessments we used the same scoring system as Drogemoller,
because this system can be applied to adults, in contrast to the Chang scoring system which is only used
for children [13,15]. We are the first to use clinically-determined ototoxicity as well, as this is a clinically
relevant outcome measure reflecting the patients’ perspective. However, it remains a subjective
outcome, which can be influenced by the interpretation of different investigators. Interestingly we
could detect an association between the genetic variant in ACYP2 when using the clinical measure
but not for audiometrically determined ototoxicity. The reason for the discrepancy between clinical
and audiometrical determined ototoxicity is speculative. Audiometrical determined ototoxicity is
obviously more objective, but clinical assessed ototoxicity is probably more relevant for the patient.
In the meta-analysis that we performed, our study had the same direction of effect (OR > 1) as the
other studies.
Cisplatin-induced sensorineural hearing loss can best be evaluated with bone conduction
measurements as this specifically measures the hearing of the inner ear/cochlea [29].
Theunissen et al. [29] argued that air conduction thresholds represent the functionality of the whole
auditory system, including both air and bone conduction, and felt that the grading criteria should
comprehend the overall hearing loss due to treatment as this is eventually the clinically relevant
hearing loss the patient experiences.
However, to address the underlying mechanism of cisplatin-associated hearing loss and the
relation with genetic variants, we decided to perform an association analysis using both air and bone
conduction hearing tests, but we did not find any association between the studied genetic variants and
the two ototoxicity outcomes.
With respect to SNPs as predictive markers for nephrotoxicity, the genetic variant in OCT2 was
found to be significant associated with nephrotoxicity at any point during chemoradiotherapy, but not
with nephrotoxicity at end of treatment. To our knowledge, only two studies have been performed
to assess the relationship between OCT2 and cisplatin-induced nephrotoxicity in humans. [21,30].
Filipski et al. [21] investigated the effect of the rs316019 variant in OCT2 in 78 cancer patients receiving
cisplatin. Renal function was determined one day before and 1–8 days after the first dose cisplatin.
Iwata et al. investigated the rs316019 variant of OCT2 in 53 patients receiving cisplatin during more
cycles. Remarkably, both Iwata et al. and Filipski et al. showed that the presence of T of the genetic
variant rs316019 in OCT2 was ameliorating cisplatin-induced nephrotoxicity, whereas our study found
the opposite. The variation in the results might be related to the different endpoints for nephrotoxicity
that have been used. Based on the previous studies and ours, we believe that at the moment the use of
this SNP is not relevant for clinical practice.
In our study, patients treated with high dose cisplatin and intermediate dose cisplatin were taken
together, because of the small number of patients treated with the high dose schedule. Therefore we
cannot draw conclusion regarding association between SNPs and toxicity for specific cisplatin dosages,
while we know from previous studies that high dose cisplatin induces higher rates of ototoxicity as
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well as nephrotoxicity. These data could be of particular interest, as several studies demonstrated the
ability to enhance chemosensitivity to cisplatin in HNC, thus reducing the dosage needed, through the
down-regulation of molecules related to cell death. [31,32]
A limitation of our study is that we were not able to reach the planned sample size of 100 patients,
due to lack of DNA of 10 patients, resulting in a somewhat smaller patient cohort. Furthermore,
because of the relative small patient population, we did not correct for multiple testing and could
not perform subgroup analyses. Therefore this study should be viewed as the first steps in the link
between the studied genes and toxicities in LAHNC patients.
5. Conclusions
This is the first study to the association of ACYP2 and cisplatin-induced ototoxicity in LAHNC
patients and the fifth to describe the possible predictive value of ACYP2 regarding (clinical determined)
cisplatin-induced ototoxicity. These findings should be validated in a large cohort, to finally determine
the predictive value of ACYP2 in ototoxicity. As personalized medicine is getting more important,
these findings could eventually provide better tailored, individualized treatment for LAHNC patients
considering both oncologic efficacy as well as toxicity and quality of life, as other treatment regimens
are available such as radiotherapy with cetuximab or carboplatin.
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